Table 3 Associations between methylation levels of BIN1 promoter and CSF biomarkers after adjusting interactions between methylation and APOE ε4 status.

From: Association between methylation of BIN1 promoter in peripheral blood and preclinical Alzheimer’s disease

Variable

Model1 (BIN1)

Model2 (BIN1_01)

BIN1

BIN1×APOE

BIN1_01

BIN1_01×APOE

β

p

β

p

β

p

β

p

CSF Aβ42

18.5643

0.0038

10.9614

0.5008

2.1285

0.0029

10.6084

0.5142

CSF p-tau

−1.2903

0.8391

−37.9497

0.0195

−0.2277

0.7479

−37.2680

0.0216

CSF t-tau

−5.7126

0.3614

−19.6861

0.2176

−0.6670

0.3394

−19.4800

0.2220

CSF p-tau/Aβ42

−19.8966

0.0018

−27.8422

0.0857

−2.3084

0.0011

−27.2482

0.0921

CSF t-tau/Aβ42

−20.9574

0.0009

−24.9688

0.1202

−2.4083

0.0006

−24.5243

0.1265

  1. Bold indicated that the results were statistically significant.
  2. Multiple linear regression models were used to test the associations between methylation levels of BIN1 promoter and CSF biomarkers, adjusting for age, gender, education, APOE ɛ4 status, and interaction between methylation and APOE ε4 status.
  3. CSF cerebrospinal fluid, Aβ amyloid-β, p-tau phosphorylated tau protein, t-tau total tau protein, APOE apolipoprotein E gene, BIN1 bridging integrator 1 gene promoter, BIN1_01 01 region of bridging integrator 1 gene promoter.
Back to article page